AU2012216632A1 - Crystallization Method and Bioavailability - Google Patents
Crystallization Method and BioavailabilityInfo
- Publication number
- AU2012216632A1 AU2012216632A1 AU2012216632A AU2012216632A AU2012216632A1 AU 2012216632 A1 AU2012216632 A1 AU 2012216632A1 AU 2012216632 A AU2012216632 A AU 2012216632A AU 2012216632 A AU2012216632 A AU 2012216632A AU 2012216632 A1 AU2012216632 A1 AU 2012216632A1
- Authority
- AU
- Australia
- Prior art keywords
- bioavailability
- crystallization method
- crystallization
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000036912 Bioavailability Effects 0.000 title 1
- 230000035514 bioavailability Effects 0.000 title 1
- 238000002425 crystallisation Methods 0.000 title 1
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2016219653A AU2016219653B2 (en) | 2010-02-06 | 2016-08-25 | Crystallization Method and Bioavailability |
Applications Claiming Priority (20)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US30211010P | 2010-02-06 | 2010-02-06 | |
US61/302,110 | 2010-02-06 | ||
US31287910P | 2010-03-11 | 2010-03-11 | |
US61/312,879 | 2010-03-11 | ||
US31850310P | 2010-03-29 | 2010-03-29 | |
US61/318,503 | 2010-03-29 | ||
US33304110P | 2010-05-10 | 2010-05-10 | |
US33302810P | 2010-05-10 | 2010-05-10 | |
US61/333,028 | 2010-05-10 | ||
US61/333,041 | 2010-05-10 | ||
US35954410P | 2010-06-29 | 2010-06-29 | |
US61/359,544 | 2010-06-29 | ||
US12/847,568 | 2010-07-30 | ||
AUPCT/US2010/043892 | 2010-07-30 | ||
AUPCT/US2010/043916 | 2010-07-30 | ||
US37981410P | 2010-09-03 | 2010-09-03 | |
US61/379,814 | 2010-09-03 | ||
US45577810P | 2010-10-26 | 2010-10-26 | |
US61/455,778 | 2010-10-26 | ||
PCT/US2011/023427 WO2011097269A1 (en) | 2010-02-06 | 2011-02-02 | Crystallization method and bioavailability |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2011/023427 Division WO2011097269A1 (en) | 2009-07-31 | 2011-02-02 | Crystallization method and bioavailability |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2016219653A Division AU2016219653B2 (en) | 2010-02-06 | 2016-08-25 | Crystallization Method and Bioavailability |
Publications (2)
Publication Number | Publication Date |
---|---|
AU2012216632A1 true AU2012216632A1 (en) | 2012-09-20 |
AU2012216632B2 AU2012216632B2 (en) | 2016-05-26 |
Family
ID=44355747
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2012216632A Ceased AU2012216632B2 (en) | 2010-02-06 | 2012-09-04 | Crystallization Method and Bioavailability |
AU2016219653A Ceased AU2016219653B2 (en) | 2010-02-06 | 2016-08-25 | Crystallization Method and Bioavailability |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2016219653A Ceased AU2016219653B2 (en) | 2010-02-06 | 2016-08-25 | Crystallization Method and Bioavailability |
Country Status (15)
Country | Link |
---|---|
EP (1) | EP2531200B1 (en) |
JP (2) | JP5792748B2 (en) |
AU (2) | AU2012216632B2 (en) |
CA (1) | CA2826548A1 (en) |
CY (1) | CY1119192T1 (en) |
DK (1) | DK2531200T3 (en) |
ES (1) | ES2638072T3 (en) |
HR (1) | HRP20171201T1 (en) |
HU (1) | HUE035744T2 (en) |
IL (1) | IL221306A0 (en) |
LT (1) | LT2531200T (en) |
PL (1) | PL2531200T3 (en) |
PT (1) | PT2531200T (en) |
SI (1) | SI2531200T1 (en) |
WO (1) | WO2011097269A1 (en) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2458996B1 (en) * | 2009-07-31 | 2016-09-07 | Thar Pharmaceuticals, Inc. | Novel oral forms of a phosphonic acid derivative |
US20160016982A1 (en) | 2009-07-31 | 2016-01-21 | Thar Pharmaceuticals, Inc. | Crystallization method and bioavailability |
US9169279B2 (en) | 2009-07-31 | 2015-10-27 | Thar Pharmaceuticals, Inc. | Crystallization method and bioavailability |
SI2459176T1 (en) | 2009-07-31 | 2018-01-31 | Gruenenthal Gmbh | Crystallization method and bioavailability |
LT2531200T (en) * | 2010-02-06 | 2017-09-25 | Grünenthal GmbH | Crystallization method and bioavailability |
US9340565B2 (en) | 2010-11-24 | 2016-05-17 | Thar Pharmaceuticals, Inc. | Crystalline forms |
CN102268023B (en) * | 2011-08-15 | 2013-04-17 | 南京丰融化学技术有限公司 | Crystal form of cefroxadine (CXD) derivative |
US11654152B2 (en) | 2012-05-14 | 2023-05-23 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating disease |
US10493085B2 (en) | 2012-05-14 | 2019-12-03 | Antecip Bioventures Ii Llc | Neridronic acid and other bisphosphonates for treating complex regional pain syndrome and other diseases |
US10016445B2 (en) | 2012-05-14 | 2018-07-10 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
US10413561B2 (en) | 2012-05-14 | 2019-09-17 | Antecip Bioventures Ii Llc | Neridronic acid and other bisphosphonates for treating complex regional pain syndrome and other diseases |
US10463682B2 (en) | 2012-05-14 | 2019-11-05 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating low back pain |
US9999629B2 (en) | 2012-05-14 | 2018-06-19 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
US9956238B2 (en) | 2014-05-15 | 2018-05-01 | Antecip Bioventures Ii Llc | Compositions for administration of zoledronic acid or related compounds for treating low back pain |
US20140349974A1 (en) * | 2014-08-12 | 2014-11-27 | Antecip Bioventures Ii Llc | Zoledronic acid dosage forms for the treatment of pain |
US20130303488A1 (en) * | 2012-05-14 | 2013-11-14 | Herriot Tabuteau | Compositions Comprising Zoledronic Acid or Related Compounds for Treatment of Complex Regional Pain Syndrome |
US10350227B2 (en) | 2012-05-14 | 2019-07-16 | Antecip Bioventures Ii Llc | Neridronic acid for treating complex regional pain syndrome |
US10413560B2 (en) | 2012-05-14 | 2019-09-17 | Antecip Bioventures Ii Llc | Dosage forms for oral administration of zoledronic acid or related compounds for treating disease |
US10188617B2 (en) | 2013-03-12 | 2019-01-29 | The Board Of Trustees Of The Leland Stanford Junior University | Modulation of cellular DNA repair activity to intercept malignancy |
EP3915565A3 (en) * | 2013-03-15 | 2022-03-16 | XORTX Therapeutics Inc. | Xanthine oxidase inhibitor formulations |
CN108434154A (en) * | 2013-10-25 | 2018-08-24 | 安泰赛普生物风投二代有限责任公司 | The oral administration composition of zoledronic acid or related compound for treating disease |
CA2997378A1 (en) * | 2015-09-18 | 2017-03-23 | Grunenthal Gmbh | Crystallization method and bioavailability |
WO2017208070A1 (en) | 2016-05-31 | 2017-12-07 | Grünenthal GmbH | Bisphosphonic acid and coformers with lysin, glycin, nicotinamide for treating psoriatic arthritis |
KR20180069277A (en) * | 2016-12-15 | 2018-06-25 | 제이투에이치바이오텍 (주) | 3-Component cocrystal |
GB2571696B (en) | 2017-10-09 | 2020-05-27 | Compass Pathways Ltd | Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced |
WO2020212952A1 (en) | 2019-04-17 | 2020-10-22 | Compass Pathfinder Limited | Treatment of depression and other various disorders with psilocybin |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6677320B2 (en) * | 2000-01-20 | 2004-01-13 | Hoffmann-La Roches Inc. | Parenteral bisphosphonate composition with improved local tolerance |
CA2454200A1 (en) | 2001-07-17 | 2003-01-30 | Teva Pharmaceutical Industries Ltd. | Dosage forms for immediate gastric release of a calcium transport stimulator coupled with delayed gastric release of a bis-phosphonate |
US20040220264A1 (en) * | 2003-03-17 | 2004-11-04 | Yu Ruey J | Bioavailability and improved delivery of acidic pharmaceutical drugs |
EP1567533B1 (en) * | 2003-07-03 | 2009-03-11 | Teva Pharmaceutical Industries Ltd. | Zoledronic acid crystal forms, zoledronate sodium salt crystal forms, amorphous zoledronate sodium salt, and processes for their preparation |
US20060068010A1 (en) | 2004-09-30 | 2006-03-30 | Stephen Turner | Method for improving the bioavailability of orally delivered therapeutics |
JO3006B1 (en) * | 2005-09-14 | 2016-09-05 | Janssen Pharmaceutica Nv | Novel Lysine Salts of 4-((Phenoxy Alkyl)Thio)-Phenoxy Acetic Acid Derivatives |
SI2459176T1 (en) * | 2009-07-31 | 2018-01-31 | Gruenenthal Gmbh | Crystallization method and bioavailability |
EP2458996B1 (en) * | 2009-07-31 | 2016-09-07 | Thar Pharmaceuticals, Inc. | Novel oral forms of a phosphonic acid derivative |
LT2531200T (en) * | 2010-02-06 | 2017-09-25 | Grünenthal GmbH | Crystallization method and bioavailability |
US9340565B2 (en) * | 2010-11-24 | 2016-05-17 | Thar Pharmaceuticals, Inc. | Crystalline forms |
CN102070668B (en) * | 2010-12-23 | 2013-07-24 | 蚌埠丰原医药科技发展有限公司 | Method for preparing zoledronic acid and sodium salt thereof by utilizing phase transfer catalyst |
-
2011
- 2011-02-02 LT LTEP11740284.2T patent/LT2531200T/en unknown
- 2011-02-02 PL PL11740284T patent/PL2531200T3/en unknown
- 2011-02-02 PT PT117402842T patent/PT2531200T/en unknown
- 2011-02-02 WO PCT/US2011/023427 patent/WO2011097269A1/en active Application Filing
- 2011-02-02 HU HUE11740284A patent/HUE035744T2/en unknown
- 2011-02-02 SI SI201131269T patent/SI2531200T1/en unknown
- 2011-02-02 JP JP2012552048A patent/JP5792748B2/en not_active Expired - Fee Related
- 2011-02-02 CA CA2826548A patent/CA2826548A1/en not_active Abandoned
- 2011-02-02 ES ES11740284.2T patent/ES2638072T3/en active Active
- 2011-02-02 EP EP11740284.2A patent/EP2531200B1/en active Active
- 2011-02-02 DK DK11740284.2T patent/DK2531200T3/en active
-
2012
- 2012-08-05 IL IL221306A patent/IL221306A0/en unknown
- 2012-09-04 AU AU2012216632A patent/AU2012216632B2/en not_active Ceased
-
2015
- 2015-08-06 JP JP2015156109A patent/JP6190429B2/en not_active Expired - Fee Related
-
2016
- 2016-08-25 AU AU2016219653A patent/AU2016219653B2/en not_active Ceased
-
2017
- 2017-08-04 HR HRP20171201TT patent/HRP20171201T1/en unknown
- 2017-08-07 CY CY20171100845T patent/CY1119192T1/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2012216632A1 (en) | Crystallization Method and Bioavailability | |
IL221306A0 (en) | Crystallization method and bioavailability | |
WO2011160196A9 (en) | Multidimensional-data-organization method | |
PT2459176T (en) | Crystallization method and bioavailability | |
EP2566246A4 (en) | Carrier-aggregation-based handover method | |
EP2616977A4 (en) | Discrete element method | |
EP2578380A4 (en) | Preform opening crystallization method | |
EP2637945A4 (en) | Improved connecting method | |
EP2660214A4 (en) | Crystallized glass | |
EP2636463A4 (en) | Forming method and forming device | |
EP2631894A4 (en) | Label and method for producing same | |
EP2527939A4 (en) | Safety-augmenting base and method for controlling same | |
EP2569068A4 (en) | Separation method | |
EP2523570A4 (en) | Carrying system | |
EP2589656B8 (en) | Gene introduction method | |
EP2639883A4 (en) | Conductive member and method for producing same | |
EP2634273B8 (en) | Oxidation method | |
RS56165B1 (en) | Crystallization method and bioavailability | |
AU2013206384B2 (en) | Improved Connecting Method | |
AU2010901800A0 (en) | Membrane-Meniscus Method | |
AU2013204145B2 (en) | Pure erlotinib | |
AU2010903613A0 (en) | Therapeutic method | |
AU2010905008A0 (en) | Improved Connecting Method | |
AU2010904285A0 (en) | Well De-Liquefying System and Method | |
AU2010901728A0 (en) | Smelting method |